Synonyms for hyperstimulation or Related words with hyperstimulation

ohss              ovarial              hyperprolactinemia              pcos              polycysitic              hypoestrogenism              hysteromyoma              hyperandrogenism              preeclainpsia              leiomyomata              polycycstic              hyperthecosis              hypercorticism              orchiectomy              underactive              mastalgia              prolactinoma              vipomas              panhypopituitarism              amenorrhea              gynecomastia              endometrium              acromegalia              anovulatory              myomas              fibroids              thyroidal              prostatism              metrofibroma              castration              pregnancyhistory              oligoovulation              oligomenorrhea              prostatomegaly              adenomyosis              acromegaly              hypergonadotropic              hyperandrogenemia              folliculogenesis              craniopharyngeoma              ovulatory              luteinization              luteolysis              epithetical              hyperstimulants              approvedtrh              hepatocarcinomas              andropause              hypergonadism              virilizing             



Examples of "hyperstimulation"
The presumed pathogenesis is that primary hypothyroidism causes enlargement and hyperstimulation of the pituitary gland which in turn cause ovarian hyperstimulation, ovarian cysts and precocious puberty.
Treatment of OHSS depends on the severity of the hyperstimulation.
The hyperstimulation of the ovaries in practices like IVF can result in mild "ovarian hyperstimulation syndrome" (OHSS) in more than 20% of cases. This same hyperstimulation can cause severe OHSS in up to 2% of cases. OHSS can have serious consequences, including respiratory problems, renal impairment and even stroke.
Ovarian hyperstimulation is the stimulation to induce development of multiple follicles of the ovaries. It should start with response prediction by e.g. age, antral follicle count and level of anti-Müllerian hormone. The resulting prediction of e.g. poor or hyper-response to ovarian hyperstimulation determines the protocol and dosage for ovarian hyperstimulation.
In contrast, when referring to treating menstrual disorders, such as oligoovulation or anovulation, the preferred term is ovulation induction. In this article, unless otherwise specified, hyperstimulation will refer to hyperstimulation as part of IVF.
"Coasting", which is ovarian hyperstimulation without induction of final maturation, does not significantly decrease the risk of ovarian hyperstimulation syndrome (OHSS), according to a Cochrane review of randomized trials.
The procedure of collecting ova may or may not include ovarian hyperstimulation.
It is also a major determinant of the success of ovarian hyperstimulation.
Embryo cryopreservation is generally performed as a component of in vitro fertilization (which generally also includes ovarian hyperstimulation, egg retrieval and embryo transfer). The ovarian hyperstimulation is preferably done by using a GnRH agonist rather than human chorionic gonadotrophin (hCG) for final oocyte maturation, since it decreases the risk of ovarian hyperstimulation syndrome with no evidence of a difference in live birth rate (in contrast to fresh cycles where usage of GnRH agonist has a lower live birth rate).
Endogenous sulfur dioxide also diminishes myocardial damage, caused by isoproterenol adrenergic hyperstimulation, and strengthens the myocardial antioxidant defense reserve.
Endogenous sulfur dioxide also diminishes myocardial damage, caused by isoproterenol adrenergic hyperstimulation, and strengthens the myocardial antioxidant defense reserve.
Uterine hyperstimulation or hypertonic uterine dysfunction is a potential complication of labor induction. It is defined as either a series of single contractions lasting 2 minutes or more OR a contraction frequency of five or more in 10 minutes. Uterine hyperstimulation may result in fetal heart rate abnormalities, uterine rupture, or placental abruption. It is usually treated by administering terbutaline.
IVF using no drugs for ovarian hyperstimulation was the method for the conception of Louise Brown. This method can be successfully used when women want to avoid taking ovarian stimulating drugs with its associated side-effects. HFEA has estimated the live birth rate to be approximately 1.3% per IVF cycle using no hyperstimulation drugs for women aged between 40–42.
Ovarian hyperstimulation also includes suppression of spontaneous ovulation, for which two main methods are available: Using a (usually longer) GnRH agonist protocol or a (usually shorter) GnRH antagonist protocol. In a standard long GnRH agonist protocol the day when hyperstimulation treatment is started and the expected day of later oocyte retrieval can be chosen to conform to personal choice, while in a GnRH antagonist protocol it must be adapted to the spontaneous onset of the previous menstruation. On the other hand, the GnRH antagonist protocol has a lower risk of ovarian hyperstimulation syndrome (OHSS), which is a life-threatening complication.
Thus, in short, a GnRH antagonist protocol may be harder to schedule timewise but has shorter cycle lengths and less (or even eliminated) risk of ovarian hyperstimulation syndrome.
Some patients with ovarian hyperstimulation syndrome may have mutations in the gene for FSHR, making them more sensitive to gonadotropin stimulation.
Luteinizing hormone (LH) in addition to FSH has evidence of increased pregnancy rate, but not of live birth rate. Using low dose human chorionic gonadotropin (hCG) to replace FSH during the late follicular phase in women undergoing hyperstimulation as part of IVF does not seem to reduce the chances of ongoing and clinical pregnancy, and likely results in an equivalent number of oocytes retrieved, but with less expenditure of FSH. Administration of progestogen before hyperstimulation has evidence of improved pregnancy outcomes, while that of combined oral contraceptive pills before hyperstimulation has poorer pregnancy outcomes.
There is no evidence for an increased risk of ovarian hyperstimulation syndrome (OHSS) with IVF when compared with ovarian stimulation combined with IUI.
Ciglitazone significantly decreases VEGF production by human granulosa cells in an in vitro study, and may potentially be used in ovarian hyperstimulation syndrome.
Rare adverse events (<1% of people) include: high blood level of triglycerides, liver inflammation, reversible baldness and/or ovarian hyperstimulation syndrome.